Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression

Cancer Research

Volumn 61, Issue 23, 2001, Pages 8513-8519

  Geiger, James D ^a   Hohenkirk, Lyndon F ^a   McKenna, Elizabeth A ^a   Yanik, Gregory A ^a   Levine, John E ^a   Chang, Alfred E ^a   Mulé, James J ^a   Hutchinson, Raymond J ^b   Braun, Thomas M ^c  

^a Graduate Program in Cancer Biology   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; COLONY STIMULATING FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL LYSATE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; FEMALE; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; LEUKAPHERESIS; MALE; MONOCYTE; NEUROBLASTOMA; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LEUKAPHERESIS; MALE; NEOPLASMS; T-LYMPHOCYTES; VACCINATION;

EID: 0035576891     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cancer surveillance series: Recent trends in childhood cancer incidence and mortality in the United States
2. Late effects of treatment in survivors of childhood acute myeloid leukemia
3. Second cancers following pediatric Hodgkin's disease
4. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
5. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
6. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
7. Crosspriming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
8. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
9. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
10. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
11. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
14. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
15. Progress in active specific immunotherapy of prostate cancer
16. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells
17. Generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4. TNF-α, IL-1 β, and agonistic anti-CD40 monoclonal antibody
18. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
19. Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression
20. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines
21. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
22. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells
23. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
24. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein
25. Potency analysis of peptide, lysate, and apototic cells as sources of antigen(s) in dendritic cell-based immunotherapy in vivo
26. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide
27. Therapeutic vaccines for melanoma: Progress and problems
28. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity
29. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
30. Migration of human dendritic cells after injection in patients with metastatic malignancies
31. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
32. Direct detection of cellular immune responses to cancer vaccines
33. Monitoring specific T-cell responses to melanoma vaccines: ELIS-POT, tetramers, and beyond
34. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
35. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes
36. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
37. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression